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Abstract
Background: Chromosomal aberrations of BCL11A at 2p16.1 have been reported in a variety of
B-cell malignancies and its deficiency in mice leads to a profound block in B-cell development.
Results: Alternative pre-mRNA splicing of BCL11A produces multiple isoforms sharing a common
N-terminus. The most abundant isoform we have identified in human lymphoid samples is BCL11A-
XL, the longest transcript produced at this locus, and here we report the conservation of this major
isoform and its functional characterization. We show that BCL11A-XL is a DNA-sequence-specific
transcriptional repressor that associates with itself and with other BCL11A isoforms, as well as
with the BCL6 proto-oncogene. Western blot data for BCL11A-XL expression coupled with data
previously published for BCL6 indicates that these genes are expressed abundantly in germinal-
center-derived B cells but that expression is extinguished upon terminal differentiation to the
plasma cell stage. Although BCL11A-XL/BCL6 interaction can modulate BCL6 DNA binding in vitro,
their heteromeric association does not alter the homomeric transcriptional properties of either on
model reporter activity. BCL11A-XL partitions into the nuclear matrix and colocalizes with BCL6
in nuclear paraspeckles.
Conclusion: We propose that the conserved N-terminus of BCL11A defines a superfamily of
C2HC zinc-finger transcription factors involved in hematopoietic malignancies.
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Introduction
Malignancies of mature B lymphocytes are characterized
by chromosomal translocations involving the immu-
noglobulin heavy chain (IGH) locus on chromosome
14q32.3, resulting in the deregulated expression of the
translocated proto-oncogene. Although
t(2;14)(p16.1;q32.3) is a rare event in B cell malignancies,
gains and amplifications of 2p16.1 (previously mapped as
2p13) have been reported in approximately 20%–50%
among subtypes of diffuse large B-cell lymphoma
(DLBCL) and in 50% of classical Hodgkin's lymphoma
(HL) [1,2]. Previously we identified a Krüppel zinc finger-
encoding gene, B-cell lymphoma/leukemia 11A
(BCL11A) and showed it to be disrupted and deregulated
in four aggressive cases of B-cell chronic lymphocytic
leukemia (B-CLL) with t(2;14)(p16.1;q32.3) that lacked
mutations within their expressed variable (VH) region
genes [3-5]. The mouse orthologue, Evi9, was identified as
a proto-oncogene by virtue of nearby recurrent retroviral
insertions that correlated with the development of mye-
loid leukemias or B-cell lymphomas [6,7].
Alternative pre-mRNA splicing of human BCL11A (Figure
1) leads to a minimum of four transcripts predicted to
Human BCL11A locus and predicted protein isoforms Figure 1
Human BCL11A locus and predicted protein isoforms. Alternative splicing within the BCL11A locus (Entrez Gene ID 
53335) leads to the creation of four major protein isoforms: eXtra Long (XL; accession AJ404611), Long (L; accession 
AJ404612), Short (S; accession AJ404613), and eXtra Short (XS; accession AY692278). Exons 1 and 2 are common to all four 
isoforms, which encode a superfamily repression domain and also an unusual C2HC zinc finger likely to be involved in protein-
protein interactions (see Discussion). Unlike the XS isoform, XL, L and S all employ at least a portion of Exon 4 (which 
encodes all six Krüppel-type C2H2 zinc fingers). Also shown are the chromosomal breakpoints [3], 1.5 kb upstream of Exon 1, 
that first were described in pediatric B-CLL patients AS and LH who bore the reciprocal translocation t(2;14) (p16.1;q32.3).Molecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
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yield protein isoforms designated as eXtra-Long (XL; 5.9
kb/125 kD), Long (L; 3.8 kb/100 kD), Short (S, 2.4 kb/35
kD) and eXtra-Short (XS, 1.5 kb/25 kD). Exons 1 and 2 are
common to all isoforms, whereas XL, L and S each utilize
at least a portion of exon 4, leading to a variable number
of C2H2 zinc fingers appended to the invariant C2HC
zinc finger at the N-terminus. BCL11A-XL  RNA is
expressed at high levels in normal as well as malignant
lymphoid tissues, including germinal center (GC) B cells,
B-CLL, follicular lymphoma (FL), and DLBCL [4,8,9]. Fur-
thermore, aside from its predominant expression within
the B-cell compartment, high levels of BCL11A-XL RNA
also accumulate in both fetal and adult brain, and in the
plasmacytoid dendritic cell [4,8].
Although less thoroughly studied, Bcl11a/Evi9 transcript
expression in the mouse mirrors that seen in the human,
with highest accumulation in brain and B lymphoid cells
[8]. B-cell development in Evi9 null mice generated by
conventional targeted disruption is blocked at the earliest
progenitor B-cell stage, underscoring the essential nature
of this locus in the immune system [10]. The mouse
equivalent of the human BCL11A-L  isoform has been
shown to interact and colocalize with BCL6, another
Krüppel zinc-finger proto-oncogene expressed highly in
the germinal center and frequently deregulated by translo-
cations in FL and DLBCL [1,7]. However, no functional
consequences of BCL11A-BCL6 colocalization have been
reported. Putative transactivation and dimerization
regions as well as a potential preferred DNA binding site
have been published for the murine L form [11].
The mouse Evi9 locus is organized quite similarly, and the
genes are extraordinarily conserved at nucleotide (94%)
and amino acid (95%) levels, placing BCL11A/Evi9 within
a small subset of "ultra-conserved" genes [12]. Nonethe-
less, a murine counterpart of the XL isoform has not been
previously described [7,11,13]. Here, we document the
conservation of BCL11A-XL in mouse (and chicken) and
we report the first functional analysis of the human
BCL11A family, with emphasis on the highly expressed XL
isoform. This isoform, as with all known BCL11A iso-
forms, has an N-terminus that encodes a distinctive 12-
amino-acid peptide as well as an atypical C2HC zinc fin-
ger; these two protein motifs are stringently conserved
among a variety of hematopoietic transcription factors
and allow the definition of a new superfamily.
Results
BCL11A-XL protein accumulates highly within the nuclear 
matrix of germinal-center lymphomas and B-cell lines and 
is evolutionarily conserved
Previous studies have documented elevated RNA levels of
BCL11A in GC-derived lymphomas such as B-CLL, FL, and
Burkitt's lymphoma [1,4,9]. Conversely, post-GC lym-
phomas, regardless of the cytogenetic status of 2p16.1,
express significantly lower RNA levels of BCL11A isoforms
(unpublished observations). We tested whether this dif-
ferential pattern of RNA expression of BCL11A extends to
the protein level. We generated the BCL11A/123 mono-
clonal antibody [14] specific to the region containing zinc
fingers 4–6 which is fully retained in BCL11A-XL, partially
shared by BCL11A-L, but excluded by alternative splicing
in BCL11A-S and BCL11A-XS (Figure 1).
BCL11A/123 detects endogenous expression of BCL11A-
XL in human B-cell lines (Figure 2) previously docu-
mented to express high levels of BCL11A RNA transcripts.
Its size (~125 kD) is indistinguishable from that observed
in vitro or when transfected (see below). As a trend, XL
protein expression prevailed among pre-GC and GC-
derived B-lymphoid cell lines, but was low to negative in
cell lines representative of late-GC or post-GC stages of B-
cell development. Among the post-GC lines, the majority
of multiple myeloma (MM) and Hodgkin's lymphoma
(HL) samples were negative for BCL11A-XL. Lastly,
BCL11A was not expressed in the majority of myeloid and
T-cell leukemias.
We fractionated lysates prepared from the Granta-452 and
Namalwa lymphoid-derived cell lines expressing high lev-
els of BCL11A-XL into cytoplasm (C), nucleoplasm (NP),
chromatin (CH), and nuclear matrix (NM). Western blot-
ting studies of lymphoid cell lines (Figure 3A) demon-
strate that the XL isoform is sequestered mostly into the
NM fraction. The L form can localize additionally into the
CH. Endogenous BCL11A expression in HEK293 cells is
moderate compared to B-lymphoid cell lines and shows a
similar enrichment of XL in the NM fraction, although
when transfected, ectopic BCL11A-XL in HEK293 local-
izes to the NP fraction as well (Figure 3A). We further
observed that BCL6 fractionated primarily into the NM
regardless of whether endogenously or exogenously
expressed (Figure 3B). Curiously, although absent in the
electronic databases and undocumented in the literature,
we easily detected BCL11A-XL in tissues and cell lines
derived from mouse and chicken (Figure 3C).
BCL11A-XL interacts with BCL6, with itself, and with the 
other BCL11A isoforms
Previous studies showed that the mouse Evi9a  L-form
colocalized and associated with BCL6 when ectopically
over-expressed in non-B cells [7]. To test this for the
human isoforms, we first performed co-immunoprecipi-
tation assays using proteins generated in vitro and in tran-
sient co-transfections of COS-7 or HEK293 cells. As
expected, human BCL11A-L interacted with BCL6 in both
assays. No interaction between BCL11A-S and BCL6 was
detected (Figure 4A). XL interacted strongly with BCL6
under these artificial conditions, but importantly, theMolecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
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endogenous complex could also be immunoprecipitated
from a B-cell line (Figure 4B). A similar series of immuno-
precipitations revealed the surprising result that all three
isoforms can interact with each other or with themselves
(Figure 4C). These data indicate that interaction faces
essential for homomeric interactions (the exons common
to all isoforms) differ from those essential for heteromeric
association with BCL6 (the exons not shared with the S
isoform). Further, they raise the possibility that the rela-
tive ratios of BCL6 and the BCL11A isoforms may deter-
mine their DNA binding or transcriptional regulatory
properties.
BCL11A-XL and BCL6 interactions affect respective DNA 
binding activities in vitro but have little effect on respective 
transcriptional repression activities in vivo
Initially we tested whether N-terminal Gal4-DNA-binding
domain (Gal4DBD) fusions of XL and the other BCL11A
isoforms could modulate transcriptional activity of a fire-
fly reporter bearing 4x-Gal4 DNA binding sites. Results of
The XL isoform of BCL11A is highly expressed in a variety of pre-GC and GC-derived B-cell malignancies Figure 2
The XL isoform of BCL11A is highly expressed in a variety of pre-GC and GC-derived B-cell malignancies. 
Western blotting using BCL11A/123 to detect BCL11A-XL in a panel of malignant lymphoid cell lines. Cell types, indicated at 
the top with individual representatives (lane numbers) are arrayed from left to right according to B-cell development status. 
ALL, B-cell acute lymphocytic leukemia; CLL, B-cell chronic lymphocytic leukemia; NHL, non-Hodgkin's lymphoma; SMZL, 
small marginal zone lymphoma; FL, follicular lymphoma; MCL, Mantle cell lymphoma; DLBCL, diffuse large B cell lymphoma; BL, 
Burkitt's lymphoma; MM, multiple myeloma; HL, Hodgkin's lymphoma. Expression is highest in samples representative of ear-
lier stages of B-cell differentiation (e.g., CLL, FL). Expression is low to negative in cell lines representative of later (post-germi-
nal-center) stages of differentiation (e.g., MM and HL). The filter was stripped and re-probed (bottom panel) with anti-β-actin 
as a loading control.Molecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
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co-transfections in HEK293 cells (BCL11A-positive; see
Figure 3A) and in the murine B-cell lines BCL1 (BCL11A-
positive, Figure 3C) and M12.4 (BCL11A-negative, data
not shown) are shown in Figure 5A. All fusion BCL11A
constructs significantly repressed transcription 5–10 fold
in both cell types. Unexpectedly, the predominantly cyto-
plasmic S isoform consistently showed higher levels of
repression than XL or L. Most of BCL11A-S was artificially
driven into the nucleus by the strong nuclear localization
sequence (NLS) present on the Gal4DBD (data not
shown). No significant alteration of BCL11A activity was
observed in the presence of the histone deacetylase inhib-
itor, trichostatin A (TSA), although consistent with previ-
ous findings, BCL6 repression was released up to 7-fold
(Figure 5B). These results indicate that homomeric BCL6
and BCL11A execute trans-repression by different mecha-
nisms.
Although BCL11A-XL and L interact with each other and
with BCL6 (Figure 4A and 4B), we observed no effect of
BCL6 on BCL11A repression in co-transfected cells (Figure
5B). Similarly, we observed no synergistic or even additive
BCL11A-XL protein accumulates in the nuclear matrix of pre-germinal center lymphomas and B cell lines Figure 3
BCL11A-XL protein accumulates in the nuclear matrix of pre-germinal center lymphomas and B cell lines. (A) 
BCL11A-XL, whether endogenous (left panel) or ectopically expressed as an N-terminal FLAG-tagged fusion in HEK293 cells 
(right panel) partitions predominantly into the nuclear matrix fraction. Cells were fractionated using the method of Reyes et al 
[15], and equivalent volumes of each fraction were loaded per lane, allowing us to assess the relative distribution by western 
blotting with BCL11A/123. Cellular compartments were fractionated as Cytoplasm (C), Nucleoplasm (NP), Chromatin (CH), 
and Nuclear Matrix (NM). BCL11A-L partitions predominantly into the chromatin-associated fraction. BCL11A-S is predomi-
nantly cytoplasmic (data not shown). Note that HEK293 cells express endogenous XL protein in the NM fraction. (B) Endog-
enous BCL6, like BCL11A-XL, accumulates within the nuclear matrix. (C) Conservation of the XL isoform is documented by 
Western blotting a murine B-cell line (BCL1), mouse whole brain tissue, and the chicken DT40 B-cell line.Molecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
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effects when various BCL11A isoforms were co-transfected
(data not shown). Since BCL6 has been shown to repress
by binding to a specific consensus motif within target
genes [17], we employed a luciferase reporter in which the
minimal SV40 promoter is appended upstream with 5×-
BCL6 binding sites in tandem. Neither BCL11A-XL nor
the other isoforms significantly affected BCL6-mediated
repression in HEK293 cells (data not shown). When these
experiments were performed in DT40 chicken-derived
pre-B cells, a modest yet consistent de-repression was
reciprocally observed (Figure 5C). The specificity of this
effect might be questioned by the fact that the non-BCL6-
interacting S isoform de-repressed to an equivalent extent.
However, since all BCL11A isoforms interact with each
other (Figure 4C), the relatively high endogenous levels of
XL in DT40 (Figure 3C) might drive an S-XL heterodimer
Interaction of BCL11A-XL with BCL6, with itself, and with other BCL11A isoforms Figure 4
Interaction of BCL11A-XL with BCL6, with itself, and with other BCL11A isoforms. (A) XL and L, but not S, asso-
ciate with BCL6. Top, in vitro translated 35S-labeled BCL11A isoforms were incubated with cell lysates of HEK293 cells tran-
siently transfected with FLAG-BCL6. Complexes were immunoprecipitated with anti-FLAG, separated on SDS-PAGE, and then 
visualized by fluorography. Bottom HEK293 cells were transiently cotransfected with FLAG-BCL6 and HA-BCL11A isoform 
constructs. 48 hrs post-transfection, cell lysates were prepared, immunoprecipitates were prepared with anti-FLAG and prod-
ucts resolved as above were detected by anti-HA Western blotting. (B) Identification of endogenous BCL11A-XL and BCL6 
heteromeric complexes in B-cell lines. Whole cell lysates from the Burkitt's lymphoma cell line, Raji, were immunoprecipitated 
with anti-BCL6 polyclonal antisera, resolved on SDS-PAGE and blotted for BCL11A-XL. (C) All BCL11A isoforms interact 
with each other in vitro. Immunoprecipitations were performed using in vitro translated, unlabeled Gal4-DNA-binding domain 
(Gal4DBD) alone or Gal4DBD-BCL11A isoform fusion proteins, and in vitro translated 35S-labeled HA-BCL11A isoforms, in 
the presence or the absence of an anti-Gal4-DNA-binding domain antibody (anti-Gal4DBD). The immunoprecipitated products 
were separated on SDS-PAGE and visualized by fluorography.Molecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
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Transcriptional and DNA binding effects of BCL11A homomeric and BCL11A-BCL6 heteromeric complexes on artificial target  genes Figure 5
Transcriptional and DNA binding effects of BCL11A homomeric and BCL11A-BCL6 heteromeric complexes 
on artificial target genes. (A) Gal4DBD-BCL11A isoforms repress Gal4-mediated Firefly luciferase activity of pG5luc in 
BCL1 and M12.4 B cells or in HEK293 cells. Dual luciferase assays were performed 48 hr post-transfection into the indicated 
cell lines on whole cell lysates shown by Western blotting to contain approximately equal amounts of Gal4-BCL11A isoforms 
(data not shown). Values are the average of three independent experiments and are expressed as percent of those obtained 
using the reporter construct and Gal4DBD alone after normalization of transfection efficiency for the activity of Renilla luci-
ferase. (B) Repression by BCL6, but not BCL11A, is TSA sensitive. pG5luc and Gal4DBD-BCL11A isoform fusions or FLAG-
BCL6 along with a firefly luciferase reporter vector containing 5×-BCL6 binding sites upstream of the minimal SV40 promoter 
(5XBCL6-SV40-Luc; REF), and a Renilla luciferase control plasmid were transiently cotransfected into HEK293 cells. Indicated 
amounts of TSA were added into the cultures 24 hr after transfection, then 24 hr later Luciferase activity was measured. The 
values represent the average of three independent experiments. BCL6 does not affect BCL11A isoform repression in HEK293 
and M12.4 cells when expressed at levels sufficient for co-immunoprecipitation. Transient co-transfections were carried out in 
triplicate, normalized and plotted as described above with pG5luc luciferase and Gal4DBD-BCL11A isoform fusions with or 
without FLAG-BCL6 or an irrelevant DNA (pCEP4) to equalize input DNA. (C) Reciprocal de-repression of BCL6 and 
BCL11A-XL in chicken DT-40 B cells. Co-transfection of FLAG-BCL6 decreases Gal4-mediated luciferase (GAL4-FF) repres-
sion of Gal4-BCL11A-XL isoforms. Co-transfection of HA-tagged BCL11A isoforms releases site-specific repression on 
5XBCL6-SV40-Luc. Cells were transfected by electroporation and dual luciferase activities measured and normalized as above. 
(D) Identification of a specific DNA binding motif for BCL11A-XL. Cyclic amplification of targets (CASTing) for consensus 
sequences. In vitro translated N-terminal HA-tagged BCL11A-XL was subjected to 5 rounds of binding/PCR with a random 17-
mer bridged by vector/cloning sites, as achieved by immobilization and immunoprecipitation with an anti-HA mAB and protein 
A beads. Cloned and sequenced candidates are aligned, with lower case letters denoting vector sequence and asterisks denot-
ing sequences that contain >1 putative consensus (indicated at the bottom). (E) BCL6-BCL11A association results in enhanced 
binding of BCL11A-XL to it target sequence. Left, EMSA performed with the BCL11A consensus oligonucleotide probe (4× 
CASTing sites as determined in [D]) using the indicated protein extract amounts (μg) prepared from single transfections of 
FLAG-BCL6 or HA-BCL11A-XL into HEK293 cells. Right, EMSA with same probe, utilizing tagged-proteins from transfected 
DT40 B cells. The remaining HA-BCL11A-XL/DNA complex is ablated by anti-HA but not affected by anti-FLAG, indicating 
that no heteromeric complex is formed. (F) BCL6/BCL11A-XL association results in subtly decreased binding of BCL6 to spe-
cific DNA target sequence. The tandem BCL6 binding site repeat was isolated as a fragment from 5XBCL6-SV40-Luc, labeled 
with 32P and used as a probe in EMSA (detailed in Methods and Materials). The indicated amounts (μg) of proteins, prepared 
from nuclear extracts of untransfected HEK293 cells or BCL11A-XL transfected HEK293, and antibodies used in super-shifts 
were added (+) or not (-) to a constant amount (2 μg) of FLAG-BCL6 prepared in the same manner.Molecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
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Dynamic colocalization of BCL11A-XL and BCL6 within nuclear paraspeckles Figure 6
Dynamic colocalization of BCL11A-XL and BCL6 within nuclear paraspeckles. (A) Colocalization of BCL11A iso-
forms with BCL6. Left Panel: COS-7 cells were transiently transfected with FLAG-epitope tagged BCL11A-XL and BCL6, and 
developed using antibodies reactive with the proteins (see Methods). Nuclei were counterstained using Hoescht 33342. Images 
were acquired by confocal microscopy. Right Panel: COS-7 cells were transiently transfected with GFP-BCL11A isoform fusion 
constructs and with a a FLAG-tagged BCL6 construct. Immunostaining was performed 24 hrs post-transfection using mono-
clonal anti-FLAG primary and rhodamine-conjugated rabbit-anti-mouse secondary antibodies, and then images were collected 
by confocal microscopy. Colocalization was determined by merging sequentially scanned images from the two channels. (B) 
Endogenously expressed BCL11A in BJAB B cells forms nuclear dots and colocalizes with BCL6 (see Methods). (C) BCL11A-
XL resides within subnuclear domains adjacent to speckles. GFP-BCL11A-XL transfected COS-7 cells were immunostained 
using an anti-SC35 mAb and rhodamine-conjugated secondary. Confocal co-localization scans were performed as above. (D) 
Transcription inhibitors alter the localization of BCL11A. COS-7 cells were transiently transfected with pEGFP-BCL11A iso-
form constructs. At 24 hrs after transfection, Actinomycin D or 5,6-dichloro-1 – D-ribofuranosylbenzimidazole (DRB) was 
added to transfected cells. Cells were observed by fluorescence microscopy 6 hrs after treatment. Untreated COS-7 cells 
transfected with the pEGFP-BCL11A isoform constructs are shown as controls. (E) Identification of BCL11A-XL, nuclear dots 
as paraspeckles by virtue of co-staining with PSP1 and PSP2/nonO/p54nrb antibodies. Also shown in the middle panel is 
BCL11A-S, characteristically localizing to the cytoplasm, which unlike BCL11A-XL does not overlap with the nuclear par-
aspeckles. (F) DNase but not RNase treatment alters the localization of BCL11A. COS-7 cells were transiently transfected 
with pEGFP-BCL11A-XL. At 24 hrs after transfection, cells were treated with RNase (C), RNase and Actinomycin D (E), 
RNase and DRB (G), DNase (D), DNase and Actinomycin D (F), or DNase and DRB (H). Cells were observed via fluorescent 
microscopy 6 hrs after treatments. Untreated COS-7 cells transfected with pEGFP-BCL11A-XL are shown as controls (A) and 
(B). Hoescht 33342 staining of corresponding nuclei is shown to the right of each green fluorescence panel.Molecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
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into the nucleus (re-addressed below and in Figure 7)
where, as shown by the GAL4-fusion data of Figure 5A, its
repression activity is strong.
We employed a reiterative oligonucleotide binding and
amplification approach (CASTing [16]) to determine a
putative DNA binding core consensus for XL as C-C-C/T-
A/G-C (Figure 5D). Although the CASTing probe pro-
duced significant non-specific binding, BCL11A-XL-trans-
fected HEK293 cell extracts bind dose dependently (Figure
5E, lanes 3–4), whereas parent cell or BCL6-transfected
extract (shown to be competent for binding its own site,
Figure 5F) do not (Figure 5E, lanes 1–2). EMSAs using
four repeats of this consensus as probe in transfected
DT40 cell extracts showed specific binding for XL as
judged by antibody super-shifts (Figure 5E, lanes 16–17).
Furthermore, binding of BCL11A-XL was significantly
enhanced as levels of BCL6-containing DT40 nuclear
extract were increased (Figure 5E, lanes 10–12). Con-
versely, we observed decreased binding for BCL6/
BCL11A-XL complexes on the BCL6 probe (Figure 5F).
Collectively these data allow us to conclude that the
human BCL11A isoforms are capable of repressing tran-
scription when tethered to an artificial promoter in a TSA-
independent manner when ectopically and transiently
over-expressed. Furthermore, BCL11A-XL appears to be
capable of site-specific DNA binding. Reciprocal effects of
BCL6 or BCL11A on their respective transcriptional
repressive activities were modest at best, even though
either protein could modulate the specific binding of the
other in vitro.
BCL11A-S is relocalized from the cytoplasm to the nucleus by interaction with BCL11A-XL or BCL11A-L Figure 7
BCL11A-S is relocalized from the cytoplasm to the nucleus by interaction with BCL11A-XL or BCL11A-L. 
COS7 cells were transiently co-transfected with GFP-BCL11A-S and either the Gal4DBD as a negative interaction control (A), 
or with Gal4DBD-BCL11A-XL (B and D) or Gal4DBD-BCL11A-L (C and E). Cells were observed 24 hr after transfection via 
fluorescence microscopy. Hoescht 33342 staining of corresponding nuclei is shown to the right of each green fluorescence 
panel.Molecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
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BCL11A-XL and BCL6 segregate within nuclear 
paraspeckles
Murine Evi9a/Bcl11a-L and BCL6 were previously
reported to colocalize within an uncharacterized "nuclear
dot" subdomain [7]. We observed BCL11A-XL to localize
exclusively within nuclear dots, and colocalized with the
major fraction of BCL6 found inside the nucleus (Figure
6A). The dot pattern for BCL11A-XL was not the result of
ectopic overexpression as it was also observed in BCL11A/
123 stains of endogenous XL-expressing B cell lines (Fig-
ure 6B, and data not shown). BCL11A-L, which showed
fewer nuclear dots and more diffuse nuclear staining than
BCL11A-XL, also appeared to colocalize with BCL6 (Fig-
ure 6A, right panel), even though at least a significant por-
tion of L partitioned to a different (chromatin) nuclear
sub-fraction biochemically (Figure 3B).
We further determined that neither the BCL11A-L nor XL-
containing nuclear dots were PML or Sp100 subnuclear
domains (data not shown). Although co-staining GFP-
BCL11A-XL transfected cells with an antibody against
SC35, a prototypic speckles marker [18], revealed a simi-
lar but non-overlapping pattern for the two proteins, GFP-
BCL11A-XL appeared instead to surround the speckles
and the nucleolus (Figure 6C). We also observed in other
experiments that some cells could randomly display curi-
ously large aggregates, or caps, of BCL11A-XL around the
nucleolus (data not shown); further experimentation
revealed that intentional blocking of transcription with
chemical inhibitors could significantly increase this peri-
nucleolar accumulation (Figure 6D). Both of these prop-
erties – adjacency to speckles and peirnucleolar
relocalization – are reminiscent of the paraspeckle nuclear
subdomain [18]. As shown in Figure 6E, our results show
clear co-localization of BCL11A-XL with two "par-
aspeckle-specific" (PSP) proteins, PSP1 and nonO/
p54nrb, demonstrating BCL11A-XL as a resident of the
paraspeckle subnuclear body. In further support of this
model, our co-immunoprecipitation experiments docu-
ment protein-protein interaction (possibly indirect)
between nonO and BCL11A-XL (data not shown).
BCL11A-XL and BCL6 are in the nuclear matrix (Figure 3),
suggesting the possibility of cross-talk between it and the
paraspeckle. Treatment of GFP-BCL11A-XL expressing
cells with RNase (alone or combined with Actinomycin
D) showed no significant effects on subcellular partition-
ing (Figure 6F). Treatment with DNase, however, led to a
more diffuse perinuclear pattern, and when transcription
was blocked, paraspeckles were completely disrupted
(Figure 6F).
Interaction with nuclear BCL11A isoforms can relocalize 
the cytoplasmic BCL11A-S to paraspeckles
BCL11A-S shows predominantly cytoplasmic localiza-
tion, although small amounts of protein appear to local-
ize diffusely within the nucleus (Figure 7). When we co-
transfected GFP-BCL11A-S with GAL4-fusions of XL or L,
we observed essentially quantitative translocation of S
into paraspeckles, apparently indistinguishable from
those of XL or L alone (Figure 7). Nuclear localization of
the XL/S or L/S heteromeric complexes was dominant, in
that cytoplasmic relocalization of XL or L by S was never
observed (Figure 7 and data not shown). These data indi-
cate that the relative ratios of S to XL may determine the
subcellular localization of the S form, which when deliv-
ered to the nucleus is the most potent repressor (Figure
5A).
Discussion
We have studied expression and functional features of the
human BCL11A family with an emphasis on the hereto-
fore uncharacterized XL isoform. Why XL expression has
eluded detection in other species is unclear, as our data
indicate that it also is a major protein isoform in mouse
and chicken. Possible contributing factors might include
the significant toxicity/apoptosis associated with XL over-
expression (data not shown) or the general difficulties in
cloning full-length mRNAs of this length (~5.9 kb),
although this transcript was indeed detected but not
described in a previous publication by another research
group [10]. We established the expression pattern of XL
and showed that it, along with S and L isoforms, can
repress transcription. BCL11A-XL can bind consensus
DNA target sites specifically. Finally, we showed that XL
localizes to paraspeckle nuclear bodies involved in RNA
metabolism, can interact with the BCL6 proto-oncogene,
and can transport repression-competent, cytoplasmic
BCL11A-S to the nucleus.
BCL11A is expressed from the earliest B-cell progenitors 
through the GC stage, but is extinguished in terminally 
differentiated plasma cells
Previous studies in human or mouse were restricted to the
RNA level. The transcription profile is highly similar in
both species, with expression primarily in the immune
and central nervous system [8,10,19]. The fact that devel-
opment of Bcl11a-deficient B cells was blocked at the ear-
liest progenitor B-cell stage [10] indicates that its
expression initiates in a stem cell compartment. Microar-
ray experiments have indicated high expression of
BCL11A transcripts in CD34+ hematopoietic stem cells
[8].
At the protein level, one notable difference between
human and mouse appears to be the absence of BCL11A
in the majority of human myeloid cell lines (Figure 2)Molecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
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even though Bcl11a was initially described in myeloid
leukemias arisen in the mouse BXH2 recombinant inbred
strain [6,7]. With few exceptions, BCL11A-XL protein is
expressed in pre-GC and GC-derived B lymphoid cell
lines, but is low to negative in cell lines representative of
late-GC or post-GC stages of B cell development. The GC-
derived Burkitt lymphomas are phenotypically diverse
and the expression of BCL11A-XL does not correlate with
the presence or absence of Epstein-Barr virus; however, as
a trend, those Burkitt's which display a type III viral
latency (a lymphoblastoid phenotype) tend to be negative
for BCL11A-XL. This trend is supported indirectly by the
observation that type III lines tend conversely to be posi-
tive for the putative repressor of BCL11A, namely, Blimp-
1 [20]. Among the post-GC lines, the majority of multiple
myeloma and Hodgkin's lymphoma samples were nega-
tive for BCL11A-XL protein. This agrees well with pub-
lished microarray data [21-24]. The probes used in
microarray experiments further indicate that all BCL11A
transcripts are coordinately down-regulated in these post-
GC cell lines.
Our related studies using BCL11A/123 for immunostain-
ing [14] indicate that XL is expressed at low to undetecta-
ble levels in most normal adult tissues but has highest
expression in hematopoietic cells. The presence of XL in
mantle zone and GC subsets while absent in normal
plasma cells is consistent with the Western data of repre-
sentative cell lines presented here.
The expression pattern of BCL11A-XL among B-cell lines
suggests that its down-regulation might be a requirement
for plasmacytic differentiation. This observation is sup-
ported by previous gene expression profiling studies
where BCL11A-XL was identified as a possible target gene
repressed by Blimp-1, a master regulator of plasma cell
development [21,24]. In support of this observation, we
have identified a subset of putative BCL11A target genes
which overlap with confirmed targets of Blimp-1 in
plasma cells (G.C.I., P.W.T., and A.L.S, unpublished
observations).
BCL11A-XL binds specifically to DNA and interacts with 
BCL6
We determined by reiterative oligonucleotide selection
that in vitro BCL11A-XL binds to the core consensus 5'-C-
C-C/T-A/G-C-3' (Figure 5E). This sequence differs from
the consensus binding sequence (5'-GGCCGGAGG-3')
determined in a similar manner for the mouse BCL11A-L
equivalent, Evi9a/CTIP1 [11]. We were unable to confirm
specific binding to this sequence for either the human L
form or for the XL and S isoforms (data not shown). The
basis for this is unclear. We noticed that nearly 25% of our
individual BCL11A-XL CASTing sequences constituted E-
boxes (CAXXTG) or contained isolated E-boxes nearby.
One particular E-box, CACCTG, can be found immedi-
ately upstream of numerous mature B-cell signature genes
(e.g., CD19, CD21, and CD37) that are modulated, like
BCL11A, by the induction or over-expression of Blimp-1
[21,24].
As shown previously for the mouse L form equivalent [7],
human XL and L also associate physically with the protein
product of the BCL6 proto-oncogene (Figures 4A and 4B).
The association of BCL11A and BCL6 also has been
recently confirmed by mass spectroscopy [25]. BCL6
encodes a multiple zinc finger-containing, sequence-spe-
cific DNA binding transcriptional repressor that is fre-
quently deregulated by translocation into IGH or into (at
least) 20 other non-IGH loci in FL and DLBCL [26]. BCL6
targets include genes involved in B cell activation, B cell
differentiation (e.g., Blimp-1), inflammation, and cell
cycle control [27,28].
Since BCL11A and BCL6 are both proto-oncogenes with
overlapping expression patterns, a clear biological signifi-
cance could be envisioned for the heterodimerization of
their protein products. Therefore, we were surprised at our
inability to demonstrate robust reciprocal effects of BCL6
and BCL11A in transcription assays, whether we used B-
cell lines negative (M12.4) or positive (BCL1, DT40) for
endogenous BCL11A (Figure 5A–C), even though BCL6/
BCL11A-XL association in vitro appears to alter DNA bind-
ing of either factor to its specific target sequence (Figures
5E and 5F). There are several technical explanations.
Nuclear matrix-associated proteins such as BCL11A-XL
and BCL6 have been shown to most efficiently transacti-
vate reporters that are integrated within chromatin – a
condition not achieved in our transient assays. Alterna-
tively, BCL11A isoform interactions in some cells might
be strongly biased toward the homomeric, leaving insuffi-
cient opportunity for BCL6 to form heteromeric interac-
tions in vivo (albeit the heterodimer can be observed in
vitro or after lysis of intact cells). An explanation we favor
is that the BCL6/BCL11A-XL interaction is merely indirect;
ie, both proteins are sequestered proximally in the same
subnuclear compartment and both associate with an
intermediary protein complex. One such intermediary
may be the Mi-2/NuRD co-repressor complex. Recent data
demonstrate the interaction of NuRD (specifically the
MTA subunits) with several transcription factors, includ-
ing p53, BCL6, BCL11B, and BCL11A [29-31]. Although
they appear to direct transcription independently, BCL6
and BCL11A may antagonize one another at the post-tran-
scriptional level to contribute to the germinal center reac-
tion through their interactions with the Mi-2/NuRD co-
repressor complex.Molecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
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BCL11A and BCL6 reside in nuclear paraspeckles
BCL6 was initially reported to colocalize with mouse
Evi9a in nuclear dots of unknown identity [7]. We have
determined by colocalization of documented markers
that the BCL11A-XL and BCL6 particles are paraspeckles.
Paraspeckles are nuclear aggregates previously shown to
contain hnRNA and three paraspeckle-specific (PSP) pro-
teins [32]. Two of these (PSP1 and nonO) were shown to
colocalize with BCL11A-XL (Figure 6E), and nonO can
form an immunoprecipitable complex with XL (data not
shown). Paraspeckles were thought to function exclu-
sively in RNA metabolism. Our data challenge that con-
tention and assign BCL11A and BCL6 as the first DNA-
binding transcription factors to reside in this compart-
ment. The subnuclear localization of BCL11A-XL in par-
aspeckles suggests that it may be involved in some
topological aspect of transcription. Indeed, as shown in
Figures 6D and 6F, transcription inhibitors and treatment
with DNase (but not RNase) can significantly alter the
subnuclear partitioning of BCL11A-XL. This was similarly
documented for PSP1 and nonO and referred to as peri-
nucleolar capping [33]. DNAse-mediated conversion to a
diffused pattern indicated that paraspeckle structure is
intimately associated with DNA structural integrity, such
as provided by the nuclear matrix and its resident pro-
teins, such as BCL11A-XL, BCL6, PSP1, and nonO.
Our subcellular localization studies may provide an alter-
native and novel explanation for the lack of functional
consequences of BCL6/BCL11A-XL interaction. Contents
of paraspeckles have been shown to translocate into
nucleoli under conditions of cellular stress [32]. Accord-
ingly, we observed under transcriptional starvation and
following cell damage with etoposide that BCL11A-XL
and BCL6 re-localized to nucleoli in U2OS osteosarcoma
cells (data not shown). Often these nuclei showed a
"donut" type pattern, in which BCL6 accumulated along
the rim, and BCL11A-XL within the center. This pattern is
strikingly similar to the "BCL6 dots" observed by electron
microscopy [34] and suggests that, under conditions of
stress/DNA damage, XL and BCL6 collaboration in vivo
may be inhibited because they are sequestered in discrete
regions of the nuclear dot and incapable of functional
association. Such conditions might exist in GC B cell
nuclei as they undergo extensive double-stranded DNA
damage during the SHM process.
BCL11A isoform complexity and hematopoietic 
malignancies
The N-terminus and C2HC zinc-finger are highly con-
served across evolution within BCL11A (Figure 1) and
among at least four other genes (EHZF, FOG1, FOG2, and
BCL11B) such as to define a superfamily [35]. All five
genes are essential to myeloid (EHZF), megakaryocytic
(FOG1 and FOG2), T-lymphoid (BCL11B) and B-lym-
phoid (BCL11A) development; three (BCL11A and B,
EHZF) have been implicated in hematological malig-
nancy [10,36-38]. In transient transfection assays,
BCL11A isoforms act as repressors (Figure 5A–C). How-
ever, consistent with what has been observed for the FOG
superfamily members [37,39], homo- and heterodimeri-
zation of BCL11A likely occurs via the conserved C2HC
zinc finger, and protein dimers might activate or repress
transcription depending on context. Like the FOG genes,
post-translational modifications of BCL11A or associated
corepressors (e.g., Mi-2/NuRD) might regulate its activity
as either a repressor or activator of transcription. We antic-
ipate that some BCL11A targets will be shared and others
will be isoform-specific.
The first 12 amino acids of the conserved N-terminus,
when tethered to GAL4DBD, are both necessary and suffi-
cient to mediate repression of transcription [40]. This N-
terminal superfamily repressor domain provides a ration-
ale for our observation that the cytoplasmic S form can
repress transcription. These data are consistent with stud-
ies of Evi9/CTIP1, indicating that a trans-repression
domain resides within the shared N-terminal region of all
isoforms [11,13]. Although each of the four BCL11A iso-
forms can homodimerize with itself or heterodimerize
with any of the other isoforms, only the nuclear forms (XL
and L) interact with BCL6. A dramatic consequence of het-
erodimerization of the cytoplasmic isoforms with the
nuclear isoforms is their nuclear translocation (shown in
Figure 7 for S) to nuclear paraspeckles when heterodimer-
ized with either XL or L forms. The data indicate that the
interactions and probably the ratios among BCL11A iso-
forms and between BCL11A and BCL6 will be important
in controlling their functions.
Conclusion
BCL11A is one representative of a superfamily of tran-
scription factors known to be involved in normal as well
as malignant hematopoetic development. BCL11A can
modulate transcription activity in vitro but in a way that
is likely to be context dependent in vivo since we have
shown that BCL11A can interact with other proteins
(namely, the BCL6 proto-oncogene) and that BCL11A
exhibits different subcellular and subnuclear compart-
mentalization according to which of the various isoforms
is examined. Here we have focused attention on the novel
XL isoform which had heretofore been undescribed. We
have shown that BCL11A-XL is a DNA-sequence-specific
transcriptional repressor in vitro, which, like the transcrip-
tion factors BCL6 and nonO, localizes to nuclear par-
aspeckles in vivo. Because of the ability of BCL11A-XL to
associate with itself as well as with other BCL11A iso-
forms, future studies of BCL11A will require a careful and
thorough description of all the alternative splice variants
produced at this locus.Molecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
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Methods
Plasmids
HA- and FLAG-N-terminally-tagged BCL11A-XL, BCL11A-
L, and BCL11A-S were constructed from human cDNAs
into the pCR3.1 mammalian expression vector (Invitro-
gen) using PCR with the same forward primer but differ-
ent reverse primers for each isoform. BCL11A-XL,
BCL11A-L and BCL11A-S were amplified by PCR with the
forward primer 5-pCR3.1-BCL11(SalI): 5'-CTACAACAG-
GTCGACATGTCTCGCCGCAAG-3', and the following
reverse primers for each of the isoforms, XL, L, and S:
BCL11A-XL:
5'ATACCTCTATTCAGTTTTTATATCATTATTCAACACTC-
GATCACTGTGCCATTTTTTCATGTGTTTCTCCAGGG-
TACTGTACACGTCA-3'
BCL11A-L:
5'-CATAGT-AGCCTGCAGGTGTCGCTGCGTCTG-3'
BCL11A-S:
5'-CATATTAGCCTGCAGCGCGGGGTCAGGGGA-3'.
N-terminal, GFP-fusions were derived from these clones
following the same PCR strategy, and the amplified
cDNAs were cloned into SmaI and BamH1 sites of pEGFP-
C1. BCL11A-XL, BCL11A-L and BCL11A-S were amplified
by PCR with the forward primer 5-pEGFP-BCL11(SalI): 5'-
CTACAACAGGTCGACATGTCTCGCCGCAAG-3' and the
following reverse primers:
BCL11A-XL:
5'-CATCACAGTGGATCCATACCTCTATTCAGT-3'
BCL11A-L:
5'-CATATTATCGGATCCGTGTCGCTGCGTCTG-3'
BCL11A-S:
5'-CATATTATCGGATCCCGCGGGGTCAGGGGA-3'
GAL4 DNA binding domain (DBD) N-terminal fusions of
each isoform utilized a similar strategy with a common
forward primer used to generate the construct for all three
isoforms, and amplified cDNAs were cloned into BamHI
and KpnI sites of pBind (Promega). All isoforms were
amplified using the same forward primer 5-GAL4DBD-
BCL11(BamHI): 5'-ATAGTCGGATCCGCAT-
GTCTCGCCGCAAG-3' and the following reverse primers:
BCL11A-XL:
5'-CGCGACGCGGGTACCTATCGAATTCTTCCA-3'
BCL11A-L:
5'-CATCACAGTGGTACCGTGTCGCTGCGTCTG-3'
BCL11A-S:
5'-CATATCAGCGGTACCCGCGGGGTCAGGGGA-3'
A full-length BCL6 mammalian expression vector, pCMV-
BCL6, was kindly provided by Dr. Riccardo Dalla-Favera.
Cell cultures
COS-7, NIH-3T3, HeLa and HEK293 cells were main-
tained in DMEM (Gibco-BRL) with 10% FBS (HyClone).
All B-cell lines (BJAB, Namalwa, Granta-452, DT-40, RAJI,
RAMOS) were maintained in RPMI-1640 media (Gibco-
BRL) with 10% FBS. The BCL11A/123 hybridoma produc-
ing anti-BCL11A-XL antibody was cultured as described
[14]. Derivation and characterization of the other cell
lines used in this study (Figure 2) may be obtained upon
request (MJSD).
Protein fractionation
Nuclear matrix fractionation was carried out according to
the method of Reyes et al [15]. Ten μl of 5 × SDS sample
buffer was added to 40 μl of a fractionated lysate (cyto-
plasm [C], nucleoplasm [NP], chromatin [CH], or nuclear
matrix [NM]) and the mixture was boiled for 5 min.
Twenty μl of extract in 1 × SDS sample buffer was loaded
for gel electrophoresis.
Western blot analysis
Cells were suspended in RIPA lysis buffer (50 mM Tris-Cl,
pH 8.0; 150 mM NaCl; 2 mM EDTA; 1% NP40; 0.1% SDS;
0.5% sodium deoxycholate; Roche complete protease
inhibitor cocktail) on ice 10 min, then cleared by centrif-
ugation. Lysates were separated by SDS-PAGE and trans-
ferred to nitrocellulose membranes (Protran BA,
Schleicher and Schuell). Primary antibodies: mouse anti-
HA monoclonal antibody (Babco), 1:1000; mouse anti-
FLAG M2 monoclonal antibody (Sigma) 1:10000;
BCL11A/123 as straight hybridoma supernatant; clone N3
anti-BCL6 rabbit polyclonal antibody (Santa Cruz Bio-
technology) 1:1000. Primary antibodies were incubated 3
hr at room temperature or at 4°C overnight, washed (PBS
with 0.05% Tween-20) 3 times, then incubated with sec-
ondary antibodies (Horseradish peroxidase-conjugated
goat anti-mouse or goat anti-rabbit [Amersham Pharma-
cia Biotech]) at 1:8000 for 1 hr at room temperature. Blots
were developed using the ECL Western blotting detection
reagent (Amersham).Molecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
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Fluorescence imaging
BCL11A and BCL6 colocalization experiments in transfectants 
(Figure 6A)
COS-7 cells were co-transfected with 1 μg of pCMV-FLAG-
BCL11A-XL (left panel) or pEGFP-BCL11A (right panel)
and 1 μg of pCMV-FLAG-BCL6 using Fugene 6 (Roche)
according to the manufacturer's instructions. 48 hr post-
transfection, cells were fixed (4% paraformaldehyde in
PBS for 10 min), washed, and then permeabilized (0.5%
Triton X-100 in PBS for 15 min). Primary antibodies were
incubated 45 minutes: BCL11A/123 straight supernatant
plus N3 anti-BCL6 1:400 in 2% BSA (left panel); M2 anti-
FLAG mAb at 1:1000 (right panel). After washing, second-
ary antibodies (Molecular Probes) were diluted 1:400 in
2% BSA and incubated 10–15 minutes (goat anti-mouse
Alexa 488 plus goat anti-rabbit Alexa 594; or rabbit anti-
mouse Alexa 594, all at 1:400). Slides were washed twice
30–45 min, and mounted with VectaStain (Vector Labs)
containing Hoescht 33342 (Sigma) at 1:1000. Cells were
viewed by sequential confocal laser scanning microscopy
(Leica SP2 AOBS).
Endogenous BCL11A and BCL6 colocalization experiments in B cells 
(Figure 6B)
BJAB or Ramos cells were washed, fixed, permeabilized,
blocked with 10% goat serum in 2% BSA for 30 min
before a 1 hr incubation with BCL11A/123 and N3 anti-
BCL6 (as above). Secondary antibodies were incubated as
above (goat anti-mouse Alexa 488, BCL11A; goat anti-rab-
bit Alexa 594, BCL6).
BCL11A colocalization experiments with SC35, PSP1, and NonO/
p54nrb (Figures 6C and 6E)
COS-7 or HEK293 were transiently transfected with 1 μg
of pEGFP-BCL11A isoforms as described above. Cells
were fixed, permeabilized, and incubated with blocking
buffer containing 3% bovine serum albumin and 0.2%
gelatin in PBS for 15 min, and then incubated with pri-
mary antibodies: Mouse anti-SC35, 1:2000 (Sigma);
mouse anti-nonO, 1:200 (kind gift of R.B. Moreland);
rabbit anti-PSP1, 1:1000 (kind gift of A. Fox and A.I. Lam-
ond). Goat anti-mouse Cy3 (1:200, Amersham) and goat
anti-rabbit Cy2 (1:200, Amersham) were then used as sec-
ondary antibodies
Immunoprecipitation
For in vitro co-immunoprecipitations, Gal4DBD-BCL11A
isoforms and 35S-labeled HA-BCL11A isoforms generated
by in vitro translation were incubated in the presence or
the absence of mouse anti-Gal4-DBD monoclonal anti-
body (Sigma) at 1:100 dilution in IP buffer (50 mM Tris-
Cl, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM EDTA,
0.25% NP-40, 1 mM DTT, 1 mM PMSF) for 1 hr at 4°C.
Protein A agarose (Sigma)/IP slurry was added and incu-
bated 1 hr at 4°C. The mixture was centrifuged and pellets
were washed extensively with IP buffer prior to separation
on 8% SDS-PAGE and visualization by phosphorimaging.
For in vivo co-immunoprecipitation of recombinant pro-
teins, HEK293 cells co-transfected with pCR3.1-HA-
BCL11A and pCMV-FLAG-BCL6 were washed, lysed in
cold RIPA buffer, pre-cleared with protein A beads for 30
min at 4°C, and then incubated with anti-FLAG at 1:100
dilution for 1 hr at 4°C. IPs were collected on protein A
beads as above, were washed in RIPA buffer, then exam-
ined by SDS-PAGE/Western blotting using anti-HA anti-
body.
For co-immunoprecipitation of endogenous BCL11A and
BCL6, 10 μl of N3 anti-BCL6 was added to the RIPA lysate
of 1 × 107 Raji cells and incubated overnight at 4°C. Rab-
bit polyclonal anti-CRM-1 (Santa Cruz Biotechnology)
was used as negative control. Complexes were pulled
down using Protein A beads, washed repeatedly with RIPA
lysis buffer, then eluted and resolved by SDS-PAGE, fol-
lowed by Western blotting the C-terminus of BCL11A
(AbCam ab19489, 1:1000 dilution in 5% milk).
Luciferase assays
HEK293, seeded at 2 × 10 5 cells and cultured for 18 hr,
were transiently co-transfected with 1 μg of pG5luc luci-
ferase reporter construct (Promega), and 1 μg of Gal4DBD
or Gal4DBD-BCL11A isoform constructs using Fugene 6.
Luciferase activity was measured 48 hr post-transfection
using the Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturer's directions.
Values were expressed as percent of those obtained using
the reporter construct and Gal4DBD alone after normali-
zation of transfection efficiency for the activity of Renilla
luciferase encoded in the Gal4DBD vector.
For B-cell lines (BCL1, M12.4 and DT-40), cells were tran-
siently co-transfected with 10 μg of pG5luc and 30 μg of
Gal4DBD or Gal4DBD-BCL11A isoform constructs by
electroporation (BioRad) under conditions empirically
determined as optimal for each cell line. Luciferase activ-
ity was measured as described above.
For co-transfection of BCL11A and BCL6, HEK293 cells
were transiently co-transfected with 1 μg of pG5luc, 1 μg
of Gal4DBD or Gal4DBD-BCL11A isoform constructs and
1 μg of pCMV-FLAG-BCL6 by Fugene 6 reagent. DT-40 B
cells were transiently co-transfected with 20 μg of
Gal4DBD or Gal4DBD-BCL11A isoform constructs and
20 μg of pCMV-FLAG-BCL6 or irrelevant DNA pCEP4. The
luciferase activity was measured as described above. For
luciferase assays of BCL6 activity, we employed a luci-
ferase reporter in which the minimal SV40 promoter is
appended upstream with 5×-BCL6 binding sites in tan-Molecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
Page 15 of 16
(page number not for citation purposes)
dem (kind gift of Vivian Bardwell) and pRL-TK (Promega)
as a transfection efficiency control.
Cyclic Amplification and Selection of Target (CASTing) 
analysis
CASTing was carried out as previously described [16] with
minor modifications. A random oligonucleotide pool of
76 nucleotides containing unique flanking sequence (5'-
CAGGTCAGTTCAGCGGATCCTGTCG(A/G/C/
T)26GAGGCGAATTCAGTGCAA-CTGCAGC-3') was ren-
dered double-stranded by second strand synthesis. Two
ng of N-terminal HA tagged BCL11A-XL in vitro transla-
tion product and 0.5 ng of anti-HA antibody 9E10 were
incubated in Binding Buffer (20 mM HEPES pH 7.9, 40
mM KCl, 6 mM MgCl2, 1 mM DTT, 0.1% NP40, 3 mg/ml
acetylated BSA, 10% glycerol, 2% Ficoll, 50 mg/ml soni-
cated salmon sperm DNA, 100 mg/ml PMSF, 1 mg/ml
aprotinin) on ice for 30 min. Recovered DNA was PCR
amplified using 5'-GCTGCAGTTGCACTGA-
ATTCGCCTC-3', and 5'-CAGGTCAGTTCAGCGGATCCT-
GTCG-3'. Five rounds of selection and amplification were
carried out and the final PCR products were subcloned
and sequenced.
Electrophoretic mobility-shift assay (EMSA)
An oligonucleotide containing four BCL11A-XL consen-
sus binding sites
5'GCACTCCCACGCCTCACTCCCACGCCTCACTC-
CCACGCCTCCCACCCCCGCC TCCCACCCCCGCCT-3'
and its complement were used as probe for Figure 5E. For
Figure 5F, the tandem BCL6 binding site repeat was iso-
lated as a fragment from 5XBCL6-SV40-Luc and used as
probe. Binding reactions used Binding Buffer as above.
Competing interests
The author(s) declare there are no competing interests.
Authors' contributions
All authors listed participated in the design and/or execu-
tion of experiments. H.L. contributed to the design and
execution of the experiments shown in Figures 4A, 4C, 5A-
F, 6A, 6D, 6F, and 7; G.C.I. to Figures 1, 3C, 6A, and 6B;
J.K.W. to Figures 5A–C, and 6A–B; T.N. to Figures 6C–E;
L.P. to Figure 1 and the content of the Discussion; B.S.L.
to Figure 3C; K.P and A.H.B. L.S. to Figure 2; M.J.S.D. to
Figures 2 and 6A; A.L.S. and L.M.S. to Figure 5F; and C.D.
to Figures 3, 4B, 5E, and 5F. G.C.I. and P.W.T. wrote the
paper, and all authors contributed to the final copy of the
paper. All authors have read and approved the final man-
uscript.
Acknowledgements
The authors would like to thank M. Ghosh and S. Maika for expert technical 
assistance, and to Dr. M. Jayaram and his laboratory for kind assistance with 
fluorescence microscopy. We also are grateful to Drs. D.K. Kim and L. 
Allred for helpful discussions and critical reading of the manuscript. The 
work was supported by the Marie Betzner Morrow Endowment to P.W.T. 
This research was supported by the Intramural Research Program of the 
NIH, National Cancer Institute, Center for Cancer Research (A.L.S., LM.S.), 
and by NIH grants 1F32CA110624-01A1 (G.C.I.) and CA092318 (H.L. and 
P.W.T.).
References
1. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott
G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Weisenburger DD,
Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R,
Fisher RI, Smeland EB, Kvaloy S, Delabie J, Simon R, Wilson WH, Jaffe
ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosen-
wald A: Diffuse Large B-Cell Lymphoma Subgroups Have Dis-
tinct Genetic Profiles that Influence Tumor Biology and
Improve Gene Expression-Based Survival Prediction.  Blood
2005, 106:3183-3190.
2. Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegel-
berger B, Grote W, Novo FJ, Calasanz MJ, Hansmann ML, Dyer MJ,
Siebert R: Recurrent involvement of the REL and BCL11A loci
in classical Hodgkin lymphoma.  Blood 2002, 99:1474-1477.
3. Fell HP, Smith RG, Tucker PW: Molecular analysis of the t(2;14)
translocation of childhood chronic lymphocytic leukemia.
Science 1986, 232:491-494.
4. Satterwhite E, Sonoki T, Willis TG, Harder L, Nowak R, Arriola EL,
Liu H, Price HP, Gesk S, Steinemann D, Schlegelberger B, Oscier DG,
Siebert R, Tucker PW, Dyer MJ: The BCL11 gene family: involve-
m e n t  o f  B C L 1 1 A  i n  l y mphoid malignancies.  Blood 2001,
98:3413-3420.
5. Kuppers R, Sonoki T, Satterwhite E, Gesk S, Harder L, Oscier DG,
Tucker PW, Dyer MJ, Siebert R: Lack of somatic hypermutation
of IG V(H) genes in lymphoid malignancies with
t(2;14)(p13;q32) translocation involving the BCL11A gene.
Leukemia 2002, 16:937-939.
6. Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG:
RTCGD: retroviral tagged cancer gene database.  Nucleic Acids
Res 2004:D523-527.
7. Nakamura T, Yamazaki Y, Saiki Y, Moriyama M, Largaespada DA,
Jenkins NA, Copeland NG: Evi9 encodes a novel zinc finger pro-
tein that physically interacts with BCL6, a known human B-
cell proto-oncogene product.  Mol Cell Biol 2000, 20:3178-3186.
8. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, Orth
AP, Vega RG, Sapinoso LM, Moqrich A, Patapoutian A, Hampton GM,
Schultz PG, Hogenesch JB: Large-scale analysis of the human
and mouse transcriptomes.  P r o c  N a t l  A c a d  S c i  U S A  2002,
99:4465-4470.
9. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A,
Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore
T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC,
Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R,
Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM:
Distinct types of diffuse large B-cell lymphoma identified by
gene expression profiling.  Nature 2000, 403:503-511.
10. Liu P, Keller JR, Ortiz M, Tessarollo L, Rachel RA, Nakamura T,
Jenkins NA, Copeland NG: Bcl11a is essential for normal lym-
phoid development.  Nat Immunol 2003, 4:525-532.
11. Avram D, Fields A, Senawong T, Topark-Ngarm A, Leid M: COUP-
TF (chicken ovalbumin upstream promoter transcription
factor)-interacting protein 1 (CTIP1) is a sequence-specific
DNA binding protein.  Biochem J 2002, 368:555-563.
12. Bejerano G, Pheasant M, Makunin I, Stephen S, Kent WJ, Mattick JS,
Haussler D: Ultraconserved elements in the human genome.
Science 2004, 304:1321-1325.
13. Avram D, Fields A, Pretty On Top K, Nevrivy DJ, Ishmael JE, Leid M:
Isolation of a novel family of C(2)H(2) zinc finger proteins
implicated in transcriptional repression mediated by chicken
ovalbumin upstream promoter transcription factor (COUP-
TF) orphan nuclear receptors.  J Biol Chem 2000,
275:10315-10322.
14. Pulford K, Banham AH, Lyne L, Jones M, Ippolito GC, Liu H, Tucker
PW, Roncador G, Lucas E, Ashe S, Stockwin L, Walewska R, Karran
EL, Gascoyne RD, Mason DY, Dyer MJS: The BCL11AXL tran-
scription factor: its distribution in normal and malignant tis-
sues and use as a marker for plasmacytoid dendritic cells.
Leukemia  in press.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2006, 5:18 http://www.molecular-cancer.com/content/5/1/18
Page 16 of 16
(page number not for citation purposes)
15. Reyes JC, Muchardt C, Yaniv M: Components of the human SWI/
SNF complex are enriched in active chromatin and are asso-
ciated with the nuclear matrix.  J Cell Biol 1997, 137:263-274.
16. Pollock R, Treisman R: A sensitive method for the determina-
tion of protein-DNA binding specificities.  Nucleic Acids Res
1990, 18:6197-6204.
17. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R: BCL-6, a POZ/
zinc-finger protein, is a sequence-specific transcriptional
repressor.  Proc Natl Acad Sci USA 1996, 93:6947-6952.
18. Lamond AI, Spector DL: Nuclear speckles: a model for nuclear
organelles.  Nat Rev Mol Cell Biol 2003, 4:605-612.
19. Leid M, Ishmael JE, Avram D, Shepherd D, Fraulob V, Dolle P: CTIP1
and CTIP2 are differentially expressed during mouse embry-
ogenesis.  Gene Expr Patterns 2004, 4:733-739.
20. Cattoretti G, Angelin-Duclos C, Shaknovich R, Zhou H, Wand D,
Alobeid B: PRDM1/Blimp-1 is expressed in human B-lym-
phocytes committed to the plasma cell lineage.  J Pathol 2005,
206:76-86.
21. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, Giltnane
JM, Yang L, Zhao H, Calame K, Staudt LM: Blimp-1 orchestrates
plasma cell differentiation by extinguishing the mature B cell
gene expression program.  Immunity 2002, 17:51-62.
22. Schwering I, Brauninger A, Klein U, Jungnickel B, Tinguely M, Diehl V,
Hansmann ML, Dalla-Favera R, Rajewsky K, Kuppers R: Loss of the
B-lineage-specific gene expression program in Hodgkin and
Reed-Sternberg cells of Hodgkin lymphoma.  Blood 2003,
101:1505-1512.
23. Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, Dalla-Fav-
era R, Carbone A: Gene expression profile analysis of AIDS-
related primary effusion lymphoma (PEL) suggests a plas-
mablastic derivation and identifies PEL-specific transcripts.
Blood 2003, 101:4115-4121.
24. Sciammas R, Davis MM: Modular nature of Blimp-1 in the regu-
lation of gene expression during B cell maturation.  J Immunol
2004, 172:5427-5440.
25. Miles RR, Crockett DK, Lim MS, Elenitoba-Johnson KS: Analysis of
BCL6 interacting proteins by tandem mass spectrometry.
Mol Cell Proteomics 2005, 4:1898-1909.
26. Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RS, Dalla-
Favera R: Alterations of a zinc finger-encoding gene, BCL-6, in
diffuse large-cell lymphoma.  Science 1993, 262:747-750.
27. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM: Control of inflam-
mation, cytokine expression, and germinal center formation
by BCL-6.  Science 1997, 276:589-592.
28. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM: BCL-6
represses genes that function in lymphocyte differentiation,
inflammation, and cell cycle control.  Immunity 2000,
13:199-212.
29. Luo J, Su F, Chen D, Shiloh A, Gu W: Deacetylation of p53 mod-
ulates its effect on cell growth and apoptosis.  Nature 2000,
408:377-381.
30. Fujita N, Jaye DL, Geigerman C, Akyildiz A, Mooney MR, Boss JM,
Wade PA: MTA3 and the Mi-2/NuRD complex regulate cell
fate during B lymphocyte differentiation.  Cell 2004, 119:75-86.
3 1 . C i s m a s i u  V B ,  A d a m o  K ,  G e c e w i c z  J ,  D u q u e  J ,  L i n  Q ,  A v r a m  D :
BCL11B functionally associates with the NuRD complex in T
lymphocytes to repress targeted promoter.  Oncogene 2005,
24:6753-6764.
32. Fox AH, Lam YW, Leung AK, Lyon CE, Andersen J, Mann M, Lamond
AI:  Paraspeckles: a novel nuclear domain.  Curr Biol 2002,
12:13-25.
33. Fox AH, Bond CS, Lamond AI: P54nrb forms a heterodimer with
PSP1 that localizes to paraspeckles in a RNA-dependent
manner.  Mol Biol Cell 2005, 16:5304-5315.
34. Puvion-Dutilleul F, Souquere-Besse S, Albagli-Curiel O: The rela-
tionship between BCL6 bodies and nuclear sites of normal
and halogenated DNA and RNA synthesis.  Microsc Res Tech
2003, 61:389-407.
35. Ippolito GC, Probst L, Wall JK, Pulford K, Shaffer AL, Tucker PW:
Hematopoiesis, hematologic malignancy, and the zinc-finger
transcription factor BCL11A.  . under consideration
36. Wakabayashi Y, Watanabe H, Inoue J, Takeda N, Sakata J, Mishima Y,
Hitomi J, Yamamoto T, Utsuyama M, Niwa O, Aizawa S, Kominami R:
Bcl11b is required for differentiation and survival of αβ T
lymphocytes.  Nat Immunol 2003, 4:533-539.
37. Tsang AP, Visvader JE, Turner CA, Fujiwara Y, Yu C, Weiss MJ, Cross-
ley M, Orkin SH: FOG, a multitype zinc finger protein, acts as
a cofactor for transcription factor GATA-1 in erythroid and
megakaryocytic differentiation.  Cell 1997, 90:109-119.
38. Bond HM, Mesuraca M, Carbone E, Bonelli P, Agosti V, Amodio N,
De Rosa G, Di Nicola M, Gianni AM, Moore MA, Hata A, Grieco M,
Morrone G, Venuta S: Early hematopoietic zinc finger protein
(EHZF), the human homolog to mouse Evi3, is highly
expressed in primitive human hematopoietic cells.  Blood
2004, 103:2062-2070.
39. Matthews JM, Kowalski K, Liew CK, Sharpe BK, Fox AH, Crossley M,
MacKay JP: A class of zinc fingers involved in protein-protein
interactions biophysical characterization of CCHC fingers
from fog and U-shaped.  Eur J Biochem 2000, 267:1030-1038.
40. Lin AC, Roche AE, Wilk J, Svensson EC: The N termini of Friend
of GATA (FOG) proteins define a novel transcriptional
repression motif and a superfamily of transcriptional repres-
sors.  J Biol Chem 2004, 279:55017-55023.